Form 4: Sutro Biopharma Executive Hans-Peter Gerber Acquires Stock Options and Restricted Stock Units

Hans-Peter Gerber, Chief Scientific Officer of Sutro Biopharma, acquired stock options for 60,000 shares and 45,000 restricted stock units (RSUs) on March 5, 2024.

Summary

• On March 5, 2024, Hans-Peter Gerber, the Chief Scientific Officer of Sutro Biopharma, acquired stock options for 60,000 shares of common stock at an exercise price of $4.54.
• These options vest monthly starting April 1, 2024, and will be fully vested by March 1, 2028.
• Gerber also acquired 45,000 Restricted Stock Units (RSUs) which represent the right to receive one share of Sutro Biopharma's common stock upon settlement.
• These RSUs vest annually, starting March 1, 2025, with full vesting by March 1, 2028.
• Both the stock options and RSUs are subject to continued service with Sutro Biopharma.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practices, suggesting confidence in the company's future, but doesn't contain any groundbreaking news.

Positives

• The acquisition of stock options and RSUs by a key executive like the Chief Scientific Officer can be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedules for both the options and RSUs incentivize long-term commitment from the executive.

Industry Context

Stock options and RSUs are common forms of executive compensation in the biotechnology industry, used to align the interests of management with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron use similar equity-based compensation to incentivize their executives.
• The vesting schedules and amounts granted are generally benchmarked against peer companies to ensure competitiveness and retention.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign of management's commitment.
• Employees may be motivated by the alignment of executive incentives with company performance.

Key Dates